Lenalidomide

Lenalidomide, the active ingredient in Lenalidomide, is an immunomodulatory agent presented as a tablet for oral use. It is classified as an antineoplastic drug and treats multiple myeloma, myelodysplastic syndromes with del(5q), and mantle cell lymphoma in adult patients.

GNH USA supplies Lenalidomide as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres and pharmacies worldwide.

Lenalidomide is employed in hematologic malignancies and related disorders, targeting abnormal plasma cells and dysplastic marrow clones.

Multiple Myeloma: improves progression‑free survival and overall response rates in combination regimens. Myelodysplastic Syndromes with del(5q): reduces transfusion dependence and induces cytogenetic remission. Mantle Cell Lymphoma: contributes to disease control when used with other agents.

Lenalidomide may cause a range of adverse reactions, varying in frequency and severity.

Common Side Effects: - Neutropenia: reduced neutrophil count increasing infection risk. - Thrombocytopenia: lowered platelet levels, potentially causing bleeding. - Fatigue: persistent tiredness affecting daily activities. - Diarrhea: loose stools that may lead to dehydration. - Rash: skin irritation or erythema. - Nausea: upset stomach, sometimes with vomiting.

Serious or Rare Side Effects: - Venous thromboembolism: blood clots in deep veins or lungs. - Secondary primary malignancies: emergence of new cancers. - Severe cutaneous reactions: Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatotoxicity: significant liver enzyme elevation. - Embryo‑fetal toxicity: high risk of birth defects if exposure occurs during pregnancy.

Before initiating Lenalidomide therapy, consider patient-specific factors and monitor appropriately.

Pregnancy risk: contraindicated in pregnancy due to teratogenicity; ensure effective contraception. Blood counts: monitor complete blood count regularly to detect cytopenias. Thrombotic risk: assess need for prophylactic anticoagulation in high‑risk patients. Renal function: adjust monitoring in patients with impaired kidney function. Drug interactions: review concomitant medications for potential interactions. Store at ambient temperature: keep tablets below 25°C in the original container, protected from moisture and light.

Lenalidomide can interact with several drug classes, requiring careful management.

Major Interactions (Avoid): - Strong CYP3A4 inducers: may reduce Lenalidomide exposure. - Anticoagulants (e.g., warfarin): increased risk of bleeding. - Immunosuppressants: heightened infection risk.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors: may modestly increase Lenalidomide levels. - NSAIDs: can exacerbate thrombocytopenia. - Live vaccines: reduced efficacy and potential safety concerns.